Modified C-ring (except Methyl In 13-position) (e.g., Double Bond Containing, Substituted, Etc.) Patents (Class 514/179)
  • Patent number: 10688045
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 23, 2020
    Assignee: The Johns Hopkins University
    Inventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
  • Patent number: 10646436
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 12, 2020
    Assignee: The Johns Hopkins University
    Inventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
  • Patent number: 10646437
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 12, 2020
    Assignee: The Johns Hopkins University
    Inventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
  • Patent number: 10632083
    Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: April 28, 2020
    Assignee: SaCSh Corp.
    Inventor: Uri Shabto
  • Patent number: 10624904
    Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 21, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Stuart Williams, Sanjib Kumar Das, Tomas Navratil, Melissa Sandahl, Janet Tully, Rozemarijn Verhoeven
  • Patent number: 10610499
    Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 7, 2020
    Assignee: SaCSh Corp.
    Inventor: Uri Shabto
  • Patent number: 10610534
    Abstract: This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof. In some embodiments, the method includes the proviso that the patient not be otherwise in need of treatment with a glucocorticoid and a glucocorticoid receptor antagonist. The treatment method can increase the patient's morning or basal cortisol level to at least about 12 ?g/dL or a standard control level, and in turn, expedite significantly the recovery of the HPA axis. The method provided herein can improve health outcomes and life-threatening complications associated with secondary adrenal insufficiency.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 7, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Andreas G. Moraitis, Pejman Cohan, Joseph K. Belanoff
  • Patent number: 10576089
    Abstract: A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: March 3, 2020
    Assignee: Marius Pharmaceuticals LLC
    Inventor: Om Dhingra
  • Patent number: 10485810
    Abstract: The invention is directed to methods and compositions for curing migraine headaches. In particular, compositions are described involving the combination of dexamethasone, lidocaine, and thiamine. The compositions are administered to patients having migraines having trigeminal or occipital neuralgia by subcutaneous injection during a single treatment session, a combination of dexamethasone, lidocaine and thiamine to several craniofacial nerves.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: November 26, 2019
    Inventor: Faro Owiesy
  • Patent number: 10441593
    Abstract: The present invention relates generally to gynecological diseases and in particular to a method for reducing pain associated with dislocation of basal endometrium.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: October 15, 2019
    Assignee: PREGLEM S.A.
    Inventors: Ernest Loumaye, Elke Bestel, Ian Osterloh
  • Patent number: 10351587
    Abstract: Methods of using 7?,11?-dimethyl-17?-hydroxy-4-estren-3-one bucyclate (I) and 7?,11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7?,11?-dimethyl-17?-hydroxy-4-estren-3-one bucyclate and 7?,11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate, and processes for their preparation.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: July 16, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard P. Blye, Hyun K. Kim
  • Patent number: 10293052
    Abstract: Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: May 21, 2019
    Assignee: MERITAGE PHARMA, INC.
    Inventors: Elaine Phillips, Malcolm Hill
  • Patent number: 10258564
    Abstract: The present invention relates generally to compositions and methods of using the same. A first aspect of the present invention comprises a composition comprising a first viscosity increasing agent; at least one polyhydric alcohol; at least one buffering agent; at least one preservative; a second viscosity increasing agent; at least one organic solvent; at least one humectant; at least one active pharmaceutical ingredient; and water, wherein the composition is buffered to a pH of about 3 to about 11.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: April 16, 2019
    Assignee: Novan, Inc.
    Inventors: Ryan Doxey, Adam Sabouni, Eleftherios Kougoulos, Nathan Stasko
  • Patent number: 10246513
    Abstract: The present invention relates to antagonists or inhibitors, which bind selectively to RANKL/OPGbp and regulate the interaction between RANKL/OPGbp and RANK/OPG. In particular, the present invention relates to an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a RANKL/OPGbppeptide for use in the treatment, prevention or alleviation of male infertility or reduced male fertility such as oligospermia or azospermia.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: April 2, 2019
    Assignee: RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL
    Inventor: Martin Blomberg Jensen
  • Patent number: 10238659
    Abstract: The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 26, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph K. Belanoff, Hazel Hunt, Onno C. Meijer, José van den Heuvel
  • Patent number: 10231979
    Abstract: Methods for modulating inflammation using progesterone metabolites are disclosed. More particularly, methods of administering progesterone metabolites, 6?-hydroxyprogesterone (6?-OHP) and 16?-hydroxyprogesterone (16?-OHP) are disclosed for mitigating inflammation in various tissue types in the body.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 19, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Avinash Shivaputrappa Patil
  • Patent number: 10202366
    Abstract: The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R1, R2 and n are as defined and described herein, in a method for promoting wound healing in a subject.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 12, 2019
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Tami Rashal, Dilara McCauley, Sharon Shacham, Erkan Baloglu
  • Patent number: 10195214
    Abstract: Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor antagonist (GRA) and steroidogenesis inhibitors, and by concomitant administration of a GRA and CYP3A inhibitors. Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of mifepristone and ketoconazole. Subjects treated with CYP3A inhibitors or steroidogenesis inhibitors may suffer from toxicity or other serious adverse reactions; concomitant administration of other drugs would be expected to increase the risk of such toxicity and adverse reactions.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: February 5, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Joseph K. Belanoff
  • Patent number: 10188664
    Abstract: Injectable pharmaceutical compositions, methods of use and formulation are disclosed. The compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 29, 2019
    Assignee: JUROX PTY LTD
    Inventors: Kirby Shawn Pasloske, Kai Lau, Sarah Jane Richardson, Amanda Aileen Willis
  • Patent number: 10188667
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: January 29, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • Patent number: 10155004
    Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: December 18, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
  • Patent number: 10137135
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: November 27, 2018
    Assignee: Allergan Sales, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Patent number: 10052336
    Abstract: Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic anti-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as non-steroidal anti-inflammatory drugs, anti-inflammatory diets, and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing the discontinuation or reduction of toxic anti-inflammatory therapy while maintaining low inflammation using non-toxic therapy.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: August 21, 2018
    Inventor: Kaplesh Kumar
  • Patent number: 10039710
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: August 7, 2018
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • Patent number: 10000525
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: June 19, 2018
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Patent number: 9980976
    Abstract: Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a glucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 inhibitor that inhibits expression or activity of REDD1, wherein the REDD1 inhibitor is administered before, concurrently with, or after the GR agonist is administered.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: May 29, 2018
    Assignee: Northwestern University
    Inventors: Irina Budunova, Gleb Baida, Joel Dudley
  • Patent number: 9982009
    Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: May 29, 2018
    Assignees: Massachusetts Institute of Technology, Yale University
    Inventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
  • Patent number: 9867776
    Abstract: Provided is a transdermal drug delivery system, which is a delivery system for transdermal absorption, having a multi-lamellar emulsion structure, including: lipids including long-chain amides, sterols, fatty acid and fatty alcohol; an emulsifier; oil; and at least one drug for transdermal administration. The transdermal drug delivery system in a multi-lamellar emulsion structure, according to the present invention, has a lamellar structure in which a layered structure visible in stratum corneum intercellular lipids of the human body is repeated, and thus has an excellent skin barrier effect and enables a drug to be effectively partitioned through skin lipids, thereby obtaining an excellent drug delivery effect.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: January 16, 2018
    Assignee: NEOPHARM CO., LTD.
    Inventors: Se Kyoo Jeong, Ji Yeon Park, Min Seok Kim, Jong Mi Lim
  • Patent number: 9827246
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 28, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith
  • Patent number: 9757393
    Abstract: The present invention provides a method for treating diabetes, hyperlipidemia or hepatic total lipids by using ergostatrien-3?-ol and its derivatives, as well as a method for decreasing blood glucose and HbA1c levels and reducing blood total cholesterol and triglyceride levels, whereas increasing blood HDL-C levels; and a method for decreasing hepatic total lipid and triacylglycerol levels; and increasing expression levels of membrane glucose transporter 4 (GLUT4) and phospho-Akt in skeletal muscle tissue, and phospho-AMPK in both skeletal muscle and liver tissue using ergostatrien-3?-ol and its derivatives.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: September 12, 2017
    Inventor: Chun-Ching Shih
  • Patent number: 9717743
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: August 1, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • Patent number: 9717237
    Abstract: Compositions are provided that provide release of insect repellant or fragrance over an extended period of time. The compositions comprise a hydrophilically-modified cross-linked silicone elastomer and an acrylic rheology modifier.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: August 1, 2017
    Inventors: Michael A. Lull, William E. McNamara, Glen T. Anderson
  • Patent number: 9643994
    Abstract: A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by crystallization or transition in association with a specified solvent. The solvent comprises at least one member selected from the group consisting of water, an aliphatic hydrocarbon, an aromatic hydrocarbon, a halogenated hydrocarbon, a linear alcohol, an alkyl ether, an acetate ester, an alkyl ketone, an N-alkylacylamide, and an alkanenitrile.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 9, 2017
    Assignee: Aska Pharmaceutical Co., Ltd.
    Inventors: Shigeki Iwashita, Hiroyuki Hayashi, Koichi Miyazaki
  • Patent number: 9643993
    Abstract: A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by dissolving an isopropanol-solvated crystal of ulipristal acetate in a mixed solvent containing ethanol and water, and crystallizing an ulipristal acetate from the solution without addition of a seed crystal to the solution.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 9, 2017
    Assignee: Aska Pharmaceutical Co., Ltd.
    Inventors: Shigeki Iwashita, Hiroyuki Hayashi, Koichi Miyazaki
  • Patent number: 9603856
    Abstract: A pharmaceutical composition for use as medicament that inhibits inhibits autocrine Human Chorionic Gonadotropin (HCG) production and thus carcinogenesis in adult human cells, the composition comprising at least a first pharmaceutically acceptable carrier and an active agent that is a competitively binding progesterone antagonist binding to steroid receptors of human cells, wherein the composition is provided in units designed for the monthly, semi-annual or annual application of the active agent in annual dosages in the range between 0.1 mg to 10.0 mg per kg of person/body-weight.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 28, 2017
    Assignee: FLAMINA HOLDING AG
    Inventor: Michael May
  • Patent number: 9579344
    Abstract: Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: February 28, 2017
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical college
    Inventor: Christopher Kevil
  • Patent number: 9555048
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 31, 2017
    Assignee: FLEXION THERAPEUTICS, INC.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 9555047
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 31, 2017
    Assignee: FLEXION THERAPEUTICS, INC.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 9545411
    Abstract: The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. Methods for treating these conditions are provided comprising systemically administering an antiprogestin and contemporaneously locally administering an antiprogestin. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: January 17, 2017
    Assignee: REPROS THERAPEUTICS INC.
    Inventors: Joseph S. Podolski, Ronald D. Wiehle
  • Patent number: 9517240
    Abstract: The present invention provides methods of preventing or delaying the development of cancer (e.g., breast cancer) in BRCA1 mutation positive patients by beginning progesterone receptor antagonist treatment at an early age (e.g., by age 35, 30, or 25). In certain embodiment, such early treatment is long-term treatment, which may substitute or delay a preventative ovariectomy, single or double mastectomy (e.g., in patients wishing to delay or avoid a mastectomy, or patients that cannot afford a mastectomy).
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: December 13, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Eva Y. H. P. Lee
  • Patent number: 9458187
    Abstract: The present invention relates to methods of treatment of inflammatory conditions using S-[4-(3-fluoro-3-methylbutyryloxy)-but-2-ynyl]6?,9?-difluoro-17?-(furan-2-yl)carbonyloxy-11?-hydroxy-16?-methyl-3-oxoandrosta-1,4-diene-17?-carbothioate (compound of formula I), a novel anti-inflammatory compound of the androstane series and its processes of preparation.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: October 4, 2016
    Assignee: Sun Pharma Advanced Research Company Limited
    Inventors: Jiten Ranchhodbhai Patel, Gopalkumar Chimanlal Patel, Gaurav Sanjivkumar Sheth, Sanjay Nandlal Mandhane, Chitturi Trinadha Rao, Rajamannar Thennati
  • Patent number: 9457060
    Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: October 4, 2016
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, David Power
  • Patent number: 9399032
    Abstract: Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: July 26, 2016
    Assignee: The General Hospital Corporation
    Inventors: Vamsi K. Mootha, Vishal Gohil, Sunil Sheth, Yuhua Ji
  • Patent number: 9358219
    Abstract: A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: June 7, 2016
    Assignee: Futura Medical Developments Limited
    Inventor: Adrian Francis Davis
  • Patent number: 9326930
    Abstract: The present invention provides compositions containing one or more calcium sequestration agents and methods for topical application of such compositions to the skin to treat skin pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, pigmentation changes due to skin aging, or any other skin conditions related with normal such as skin of color or abnormal pigmentation such as hypo- or hyper-pigmentation in humans.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: May 3, 2016
    Assignee: NEOCUTIS S.A.
    Inventor: Frank Dreher
  • Patent number: 9295680
    Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 29, 2016
    Assignee: Pop Test Oncology Limited Liability Company
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 9168264
    Abstract: The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 27, 2015
    Assignee: PREGLEM SA
    Inventors: Ernest Loumaye, Elke Bestel, Ian Osterloh
  • Patent number: 9156877
    Abstract: The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-benzylidene derivatives of the formula I, in which Y and X are each as defined in the claims and the description, to a process for preparation thereof and to the use thereof as medicaments.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: October 13, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Klar, Wolfgang Schwede, Carsten Möller, Andrea Rotgeri, Wilhelm Bone
  • Patent number: 9149525
    Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: October 6, 2015
    Assignee: EyeGate Pharmaceuticals, Inc.
    Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
  • Patent number: RE46190
    Abstract: Enzymes in the body vary among different species, and also vary among individuals of the same species. Thus, it has been demanded to develop a novel steroid-containing pharmaceutical preparation which can release a drug in a manner independent of the enzymes present in the body, and which is expected to have an efficacious therapeutic effect. Disclosed is a high-molecular weight conjugate of a steroid, comprising a structure in which a carboxylic acid group of a polymer having a polyethylene glycol moiety and a succinic acid monoamide moiety having two or more succinic acid monoamide units is ester-bonded to a hydroxy group in the steroid.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: November 1, 2016
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masayuki Kitagawa, Toshitaka Murata